 
 
Clinical Protocol  for the  
BioInsight  Study  
 
 
BioMonitor 2 In-Office Setting Insertion Safety and Feasibility 
Evaluation wit h Device Functionality Assessmen t 
 
 
 
April 11 , 2016  
 
 
 
BIOTRONIK , Inc.  
6024 Jean Road , Lake Oswego, Oregon 97035  
 
 
 
 
This document  contains confidential information for use only by investigators and 
clinical sites participating in the clinical study. Therefore, this document should be 
maintained in a secure location and should not be copied or made available for review 
by any unautho rized personnel.  
  
Version 11 -Apr-2016  Page  1 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
TABLE OF CONTENTS  
1. INTRODUCTION  ................................ ................................ ................................ ................................ .... 5 
1.1 Name of Device  ................................ ................................ ................................ ..............................  5 
1.2 Study Overview  ................................ ................................ ................................ ..............................  5 
1.3 Background  ................................ ................................ ................................ ................................ .... 5 
1.3.1  Rationale  ................................ ................................ ................................ .............................  6 
1.3.2  BioMonitor Master Study  ................................ ................................ ................................ ..... 6 
1.3.3  BioMonitor Single -center AF Detect Study  ................................ ................................ .........  7 
1.3.4  Previous Experience with the BioMonitor 2  ................................ ................................ ........  7 
1.4 Device Description ................................ ................................ ................................ ..........................  8 
1.4.1  BioMonitor 2 Device Information  ................................ ................................ .........................  8 
1.4.2 Insertion Procedure  ................................ ................................ ................................ .............  9 
1.4.3  Remote Assistant for Patient Triggering  ................................ ................................ ...........  11 
1.4.4  BIOTRONIK Home Monitoring® ................................ ................................ ........................  12 
2. STUDY DESIGN  ................................ ................................ ................................ ................................ ... 15 
2.1 Study Objectives  ................................ ................................ ................................ ...........................  17 
2.1.1  Primary Objective 1  ................................ ................................ ................................ ...........  17 
2.1.2  Secondary Objective 1  ................................ ................................ ................................ ...... 17 
2.1.3  Secondary Objective 2  ................................ ................................ ................................ ...... 17 
2.1.4  Secon dary Objective 3  ................................ ................................ ................................ ...... 17 
2.1.5  Additional Data of Interest  ................................ ................................ ................................ . 17 
2.2 Study Size and Duration  ................................ ................................ ................................ ...............  18 
2.3 Sample -Size Analysis  ................................ ................................ ................................ ...................  18 
2.3.1  Replacement of Subjects  ................................ ................................ ................................ .. 19 
2.4 Data Analyses  ................................ ................................ ................................ ..............................  20 
2.4.1  Objective Analysis  ................................ ................................ ................................ .............  20 
2.4.2  Trend Analyses  ................................ ................................ ................................ .................  20 
2.4.3  Missing Data  ................................ ................................ ................................ .....................  20 
3. PROTOCOL REQUIREMENT S ................................ ................................ ................................ ...........  22 
3.1 Subject Population ................................ ................................ ................................ ........................  22 
3.1.1  Indications  ................................ ................................ ................................ .........................  22 
3.1.2  Contraindications  ................................ ................................ ................................ ..............  22 
3.1.3  Inclusion Criteria  ................................ ................................ ................................ ...............  22 
3.1.4  Exclusion Criteria  ................................ ................................ ................................ ..............  23 
3.2 Study Procedures  ................................ ................................ ................................ .........................  23 
3.2.1  Study Pre -screening ................................ ................................ ................................ ..........  24 
3.2.2  Enrollment Visit  ................................ ................................ ................................ .................  24 
3.2.3  Insertion  ................................ ................................ ................................ ............................  25 
3.2.4  Wound Check Visit and 90 -day Follow -up ................................ ................................ ........  26 
3.2.5  Interim Follow -ups and System Revisions  ................................ ................................ ........  27 
4. DATA COLLECTION  ................................ ................................ ................................ ...........................  28 
4.1 Electronic Data C apture (EDC)  ................................ ................................ ................................ .... 28 
4.2 Electronic Case Report Forms (eCRFs) ................................ ................................ .......................  28 
4.3 Data Clarification/Data Quality Control ................................ ................................ .........................  29 
4.4 Subject Retention  ................................ ................................ ................................ .........................  29 
4.5 Subject Data Confidentiality  ................................ ................................ ................................ .........  29 
5. RISKS AND RISK MINIM ALIZATION  ................................ ................................ ................................ . 30 
6. STUDY ORGANIZATION  ................................ ................................ ................................ .....................  31 
6.6 Sponsor  ................................ ................................ ................................ ................................ ........  31 
  
Version 11 -Apr-2016  Page  2 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
6.7 Clinical  Events Committee  ................................ ................................ ................................ ...........  31 
7. STUDY MONITORING  ................................ ................................ ................................ .........................  32 
7.1 Summary  ................................ ................................ ................................ ................................ ...... 32 
7.2 Study Monitors  ................................ ................................ ................................ ..............................  32 
7.3 Monitoring Visits  ................................ ................................ ................................ ...........................  33 
7.4 Centralized Monitoring  ................................ ................................ ................................ .................  33 
8. STUDY COMPLETION  ................................ ................................ ................................ ........................  34 
9. ADVERSE EVENTS  ................................ ................................ ................................ .............................  34 
9.1 Reportable Adverse Events  ................................ ................................ ................................ ..........  34 
9.1.1  Insertion Procedure -Related Adverse Events  ................................ ................................ ... 34 
9.1.2  Device -Related Adverse Events  ................................ ................................ .......................  35 
9.1.3  Non-Proced ure Non -System Related Adverse Events  ................................ .....................  35 
9.2 Analysis of the Objectives  ................................ ................................ ................................ ............  35 
9.3 Adverse Events for the Analysis of the Primary an d Secondary Objectives  ................................  36 
9.3.1  Adverse Events for the Analysis of Primary Objective 1 ................................ ...................  36 
9.3.2  Adverse Events for the Analysis of Secondary Objective 1  ................................ ..............  36 
9.4 Adverse Event Reporting  ................................ ................................ ................................ .............  36 
10. OTHER GENERAL INFORM ATION  ................................ ................................ ................................ .... 37 
10.1  Protocol Compliance  ................................ ................................ ................................ ....................  37 
10.1.1  Protocol Violations  ................................ ................................ ................................ ............  37 
10.1.2  Protocol Deviations  ................................ ................................ ................................ ...........  37 
10.2  Study Exits  ................................ ................................ ................................ ................................ .... 38 
10.2.1  Screen Failures  ................................ ................................ ................................ .................  38 
10.2.2  Unsuccessful Insertion Procedures  ................................ ................................ ..................  38 
10.2.3  Withdrawal of Consent  ................................ ................................ ................................ ...... 38 
10.2.4  Subject Death  ................................ ................................ ................................ ....................  38 
10.2.5  BioMonitor 2 Removal  ................................ ................................ ................................ ....... 39 
10.2.6  Lost to Follow -up ................................ ................................ ................................ ...............  39 
10.2.7  Study Participation Complete  ................................ ................................ ............................  39 
10.3  Informed Consent  ................................ ................................ ................................ .........................  39 
10.4  IRB Approval  ................................ ................................ ................................ ................................  39 
10.5  Other Institutions and Physicians  ................................ ................................ ................................ . 40 
11. RECORDS AND REPORTS  ................................ ................................ ................................ ................  41 
11.1  Investigator Records ................................ ................................ ................................ .....................  41 
11.2  Investigator Reports  ................................ ................................ ................................ .....................  41 
11.3  Sponsor Records  ................................ ................................ ................................ ..........................  42 
12. REFERENCES  ................................ ................................ ................................ ................................ ..... 44 
APPENDIX A: DEFINITIO N OF TERMS  ................................ ................................ ................................ .... 45 
APPENDIX B: DETAILED  PROCEDURES  ................................ ................................ ...............................  47 
 
 
 
 
 
  
Version 11 -Apr-2016  Page  3 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
BioInsight  Study  
 
PROTOCOL SIGNATURE PAGE  
 
The signature below constitutes the receipt  and review of the BioInsight  Study  protocol  and any 
attachments, and provides the necessary assurances that this study will be conducted 
according to all stipulations of the protocol, including all statements regarding confidentiality, 
and according to lo cal legal and regulatory requirements and applicable US federal regulations, 
ICH and GCP guidelines . 
 
 
PRINCIPAL INVESTIGAT OR: 
 
 
Signed:     
 Name (please print)  
 
   
 Signature   Date  
 
  
Version 11 -Apr-2016  Page  4 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
 
Title:  BioInsight  Study  
Design:  Multi -center, prospective, non -randomized, post -market study  
Purpose:  The purpose of this study is to evaluate the safety and feasibility of  performing 
the BioMonitor 2 insertion procedure  in an office setting. The study will provide 
data to characterize insertion procedure -related advers e events, time and 
resources utilized at insertion , and device functionality post -insertion . In 
addition, the study may provide data to support an application to CMS and 
private insurance for reimbursement of in -office implants of this device.  
Subject Pop ulation:  Subjects indicated for continuous arrhythmia monitoring who are willing to 
undergo the insertion procedure in an office setting . 
Enrollment:  This study will enroll up to 75 subjects . 
Clinical Sites:  Up to 7 centers within the United States.  
Primary Objectives : Characterization  of all insertio n procedure -related adverse events  within 90 
days post -insertion  that require additional invasive intervention to resolve.  
Secondary Objectives :  Characterization of all insertion procedure -related adverse even ts. 
 Characterization of  the insertion procedure . 
 Characterization of d evice functionality post -insertion . 
Clinical Events 
Committee Chair:  Marye Gleva, M.D., F.A.C.C, F.H.R.S.  
Associate Professor of Medicine  
Department of Cardiology  
Washington Univers ity School of Medicine, St. Louis, MO  
Sponsor:  BIOTRONIK, Inc.  
Clinical Studies Department  
6024 SW Jean Road  
Lake Oswego, Oregon 97035  
 
  
Version 11 -Apr-2016  Page  5 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
1. INTRODUCTION  
1.1 NAME OF DEVICE  
This study is designed to investigate the BioMonitor 2, BIOTRONIK’s second generation 
of insertable cardiac monitor (ICM) . The BioMonitor 2 is available in one model, the 
BioMonitor 2 -AF. 
1.2 STUDY OVERVIEW  
The purpose of this study is to evaluate the safety and feasibility of performing  the 
BioMonitor 2 insertion procedure in an office setting. Data will be collected from up to 75 
subjects from insertion  through 90 -days of follow -up post-insertion .  
Subjects will be consented within 30 days prior to the insertion procedure  and will be 
screened to ensure they meet all of the inclusion and none of th e exclusion criteria. 
Subjects with successful insertions  will be required to complete an initial wound check 
visit 7 days (window -2, +7 days)  after the procedure  and a routine follow -up visit at 90 
days  (window -15, +30 days)  post-insertion . 
The rate of insertion procedure -related adverse events (AEs)  within 90 days post -
insertion  that require additional invasive intervention to resolve will be assessed . Data 
will also be collected on the safety and feasibility of in -office insertion procedures.  
Additiona lly, device orientation and insertion  techniques, time and resources utilized, 
and device functionality post -insertion  will be characterized . 
1.3 BACKGROUND  
Based on the first generation of BIOTRONIK’s ICM, the BioMonitor 2 utilizes well -
established arrhythmia  detection algorithms within smaller hardware. Equipped with 
BIOTRONIK Home Monitoring®, the BioMonitor 2 supports daily transmissions of device 
diagnostics and subcutaneous ECG  (sECG)  recordings , automatically and through 
patient triggers. The BioMonitor 2, cleared April 11 , 2016  (K152995  number) , is the 
successor of the BioMonitor  with AF detection , cleared March 19, 2015  (K143503 ).  
 
 
 
 
  
  
Version 11 -Apr-2016  Page  6 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
1.3.1  Rationale  
ICMs and implantable loop recorders (IRLs) are subcutaneous devices capable of long -
term cardiac rhythm mon itoring that are useful in correlating arrhythmias with patient 
symptoms. Most commonly, ICMs are implanted to assist  in the diagnosis of 
unexplained palpitations and syncope  with more reliable  and accurate monitoring than 
traditional 12 -channel ECG s. ICMs  are also  used in the detection and management of 
atrial fibrillation (AF) for patients who are at high thromboembolic risk. ICMs , including 
BIOTRONIK’s first generation BioMonitor,  were originally designed after pacemaker 
technology. Current ICMs have sig nificantly decreased profiles , allowing for less -
invasive insertion procedure s1 and low complication rates2-3 compared to  that of 
pacemakers and implantable cardioverter defibrillators (ICDs) .4-5 
In recent years, many minor surgical procedures have moved f rom traditional hospital 
settings to physician office settings. While performing these procedures outside of a 
hospital environment presents possible additional risks to the patient, the procedures 
are generally lower in cost and utilize fewer resources.6 With increased interest in 
performing procedures on an out -patient basis, few studies explore the safety of 
procedures outside of specialized clinics. Before new pro cedures can be adopted in an 
office setting, the procedure complexity, capabilities of the new location, and access to 
supplies, must be considered.  
Unlike other cardiac devices, I CMs do not require vascular access. The low associated 
complication rates and simplistic insertion procedure s make ICMs ideal ca ndidate s for 
in-office  device placemen t. This study explores the safety of the BioMonitor 2 insertion 
procedure in an office setting.  The study will provide data to characterize insertion 
procedure -related adverse events , time and resources utilized during insertion , and 
device functionality p ost-insertion . In addition, the study may provide data  to support  an 
application to  CMS and private insurance for reimbursement of in-office implants of this 
device . 
1.3.2  BioMonitor Master Study   
The BioMonitor Master Study  was conducted to support regulatory  approvals  of 
BIOTRONIK’s first generation of ICM and is registered on ClincalTrials.gov 
[STUDY_ID_REMOVED]. The objective of this post -market follow -up study was to  confirm the 
safety  and efficacy of the BioMonitor . There were 152 subjects implanted between 
Octobe r 2012 and October 2014 and observed over the course of one year. During the 
study, no serious complications or adverse events related to the BioMonitor  were 
reported, and overall performance of BioMonitor was within the expected range.  
  
Version 11 -Apr-2016  Page  7 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
1.3.3  BioMonitor Single -center AF Detect Study  
BIOTRONIK conducted a n AF Detection clinical study in order to a ssess the 
performance of the BioMonitor’s AF feature in clinical practice . The ability of BioMonitor 
to detect episodes of AF was quantified in comparison with the gold -standard,  expert -
annotated, external Holter ECG recorder. Fifty (50) participants with suspected 
paroxysmal or  persistent atrial fibrillation who had been implanted with a BioMonitor 
were additionally equipped with an  external Holter ECG recorder.  
Of thes e 50 participants, 27 showed at least one true AF episode  during the 48 -hour 
Holter period, with a maximum of 30 distinct, true AF episodes experienced by one  
subject . A total of 131 AF episodes were annotated from 2132.9 hours of Holter ECG 
data. During t he execution of the AF Detection study, only one subject had missing 
Holter data, and hence was excluded  from the analysis. These sensitivity values were 
used to calculate the 10,000 -sample bootstrap (with  71 of 520  replacement) 95% 
confidence interval for  AF detection sensitivity. The 95% confidence limits were 88.5  
and 99.1%. The lower 95% confidence interval for AF episode sensitivity of 88.5% 
clearly exceeds the  lower 95% confidence interval for AF episode sensitivity of >60% 
requested by FDA.  
1.3.4  Previous Experience with the BioMonitor 2  
A pilot study of the BioMonitor 2-AF device  and associated tools/accessories has been 
completed in Australia. The study followed an open, prospective, single -arm, non -
randomized design. The objective of this study was to pr ovide clinical data of the 
insertion procedure in an electrophysiology or cardiac catheterization laboratory setting , 
and sensing quality of BIOTRONIK’s second generation of ICM , the BioMonitor 2. Data 
of 30 subjects from 5 Australian clinical sites from D ecember 18, 2014 through July 06, 
2015 are included in this summary. There were 22 male and 8 female subjects enrolled 
with a mean age of 63 years. The most common indications for insertion  of the 
BioMonitor 2 were  syncope and symptomatic or asymptomatic a trial fibrillation.  
The median time between first skin cut to final successful positioning of BioMonitor 2 
was 2.5 minutes. The mean time of the entire implantation procedure was 9.9 minutes. 
Implanting investigators evaluated the tunneling procedure usin g the  fast insertion tool  
(FIT)  set comprised of FIT 1 (pocket tool) and FIT 2  (lead support tool) . The FIT 1 tool 
was evaluated related to the needed force and grip on the tool, which resulted in a 
rating of good or acceptable in 83% and 100% of the cases  respectively. The FIT 2 tool 
was evaluated by the implanting investigator for device  loading, insertion, removal and 
overall handling. All assessments were good or acceptable.  
  
Version 11 -Apr-2016  Page  8 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
The mean R -wave amplitude at the 1 -week and 1 -month follow -up visit was 0.7 ± 0 .4 
mV and 0.8 ± 0.4 mV , respectively. The results show significant superiority to the mean 
R-wave amplitude of the predecessor BioMonitor (0.3 mV). The mean noise burden was 
1.3 ± 2.3 % and 2.3 ± 3.1 % at the 1 -week and 1 -month follow -up, respectively. The  
results are significantly improved compared to the predecessor device (5.5%). Five 
subjects reported pain in the pocket during the first week after insertion . Medical 
treatment was not needed. One subject had a wound infection which was treated with 
oral antibiotics.   
The results demonstrate safety and efficacy of the insertion  procedure and the study 
device. There were no observations of pocket enlargement or device migration during 
the human clinical evaluation.  
1.4 DEVICE DESCRIPTION  
1.4.1  BioMonitor 2 Device In formation  
BIOTRONIK’s  second generation ICM, BioMonitor  2, is a programmable, subcutaneous 
device that monitors multiple parameters used for cardiac arrhythmia identification . In 
conjunction with BIOTRONIK’s Renamic/ICS 3000 Programmer and U.S. market -
released CardioMessenger® devices capable of communicating with the BioMonitor 2, 
the BioMonitor 2 is designed  to automatically provide information on the occurrence of 
arrhythmias in a patient.  The BioMonitor 2 is significantly smaller than its predecessor  
and has  a longer vector length, or electrode spacing. Although its pacemaker shaped 
predecessor achieves good signal quality by intelligent combination of three smaller 
sensing vectors , the signal amplitudes detected by BioMonitor  2 are generally  larger 
due to the  increased vector  size.  
As seen in Figure 1 below, the BioMonitor 2 is comprised of a flexible lead with an 
embedded antenna and a rigid body.  
Figure 1: BioMonitor  2  
 
The structur e and material combination allow  for ideal device placement that is 
adjustable to individual patient anatomy. The rigid portion measures 55 mm and the 
flexible portion measures 33 mm in length for a full device length of 88 mm. The device 
is 15 mm wide, 6. 2 mm thick, weighs 10.1 g , and is 5 cc in volume. The new shape and 
  
Version 11 -Apr-2016  Page  9 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
the smaller dimensions of BioMonitor  2 allow for significantly smaller incision length 
(approx. 15 mm) compared to the predecessor (approx. 40 mm) and parasternal 
placement, which is locat ed closer to the hear t than a typical pacemaker pocket.  
1.4.2  Insertion Procedure   
The BioMonitor  2 system is comprised of a specialized FIT set, consisting of the FIT 1 
(pocket tool) and FIT 2 (lead support tool), for easy sub -dermal insertion. The insertion 
tool set (as shown in Figure 2) is designed to create a snug pocket for BioMonitor  2, to 
have an ergonomic contour for the physician , and to properly support the flexible lead 
during insertion . 
Figure 2: BioMonitor 2 Insertion Tool Set  
 
BioMonitor  2 is developed for the insertion into a subcutaneous pocket, in the left side of 
the chest . The determined positions are based on the patient’s anatomy  and comfort, as 
well as cosmetic considerations. Recommended locations are areas where minimal 
device movement due to positional changes or bo dy and arm movement is expected  
(Figure 3), e.g. locations between the suprasternal notch and the left nipple, generating 
an approximately 45° rotation  from the midline (position A) or the left parasternal region 
(position B). Alternatively, a left sub -mammary position can be used (position C) . 
 

  
Version 11 -Apr-2016  Page  10 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Figure 3: Possible  Posit ions of BioMonitor  2 
 
  
In the selected anatomical position, after application of local anesthetic agent, a small 
incision through the skin is made, avoiding damage to any underlying musculature. The 
incision should be approximately 15 mm wide. The pocket tool (FIT 1) is advanced 
within a sub -dermal plane until the thumb stop approaches the incision, as shown in 
Figure 4a and 4b. After withdrawing the FIT 1 a suitable pocket for the device  is formed.   
Figure 4: Insertion of the Pocket Tool FIT 1  
 
The BioMonitor  2 is placed into the support tool, FIT 2, (Figure 5a) and inserted in a 
two-step approach: First the BioMonitor  2 is gripped with the thumb on top of the device 
until it is inserted u p to the welding line (Figure 5b). In a second step, the device is 
pushed in with the thumb resting behind the device  (Figure 5c). This ensures that both, 
the FIT 2 with the BioMonitor  2, are inserted together straight into the pre -shaped 
pocket.  
 
 
  
Version 11 -Apr-2016  Page  11 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Figure 5: Insertion of the BioMonitor  2 with the Support Tool FIT 2  
 
While sliding the support tool FIT 2 out of the pocket, finger pressure is applied to the 
BioMonitor  2 to keep the device  in place. For incision closure standard clinic al practice 
is advised. The protection of the wound from environmental influences according to 
physician preference  finalizes the insertion procedure of BioMonitor  2.  
1.4.3  Remote Assistant for Patient Triggering  
Many generations of pacemakers as well as  the fi rst generation BioMonitor offer the 
possibility to trigger an IEGM or ECG recording, respectively, if a magnet is applied over 
the device . The disadvantage of a magnet is its weight and furthermore the patient 
receives  no feedback if the recording was succ essful or not. In stead,  BioMonitor  2 
utilizes a small electronic patient device, the Remote Assistant.  
The Remote Assistant patient device is a hand -held, battery -operated device which 
uses radio -frequency and coil telemetry to communicate with the BioMon itor 2. The 
Remote Assistant is intended for unsupervised patient use away from a hospital or clinic  
to allow the patient to activate storage of cardiac data when a symptomatic event occurs 
or has  occurred . The Remote Assistant , shown in Figure 6, activates the data 
management features in the BioMonitor  2 to initiate recording of cardiac event data in 
the device memory  by the single , user -operated button located on the middle area of 
the Remote Assistant patient  device.  
Figure 6: Remote Assistant Patient Device  
 
 Record button   Telemetry status light  
Low battery light  

  
Version 11 -Apr-2016  Page  12 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
When device is placed over the location of the BioMonitor 2 implant and the record 
button is pressed, the Remote Assistant indicates if telemetry with th e device is 
successful by briefly displaying a yellow light signal. The patient can then move the 
Remote Assistant  away from their chest and view the green light signal  indicating a 
successful recording . 
1.4.4  BIOTRONIK Home Monitoring® 
The BIOTRONIK Home Monito ring® system provides early detection of arrhythmic 
events like high ventricular rates or syncope and of silent, asymptomatic events like 
atrial fibrillation , through the transmission of periodic ( Figure 7) and triggered sECG 
recordings .  
Figure 7: Periodic sECG Transmission Example  
 
The BioMonitor 2 has the capability to transmit messages to the BIOT RONIK Home 
Monitoring Service Center daily so that the responsible physician wil l have updated data 
on the technical and physiological parameters of the patient every 24 hours.  
BIOTRONIK Home Monitoring® can be used to provide the physician with advance 
reports from the BioMonitor 2 and can process them into graphical and tabular form at. 
This information helps the physician optimize the therapy process, as it allows the 
patient to be scheduled for additional clinical appointments between regular follow -up 
visits if necessary .  
Figure 8: BIOTRONIK Home Monitorin g® Transmission Path  
 
BIOTRONIK conducted the TRUST study to evaluate the safety and effectiveness of 
BIOTRONIK Home Monitoring®. BIOTRONIK received FDA approval (P050023/S020, 
approved May 12, 2009) of the following labeling claims regarding BIOTRONIK Ho me 
Monitoring®: 

  
Version 11 -Apr-2016  Page  13 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
1. BIOTRONIK Home Monitoring® information may be used as a replacement for 
device interrogation during in office follow up visits.  
2. A strategy of care using BIOTRONIK Home Monitoring® with office visits when 
needed has been shown to exten d the time between routine, scheduled in office follow 
ups of BIOTRONIK implantable devices in many patients. BIOTRONIK Home 
Monitoring® data is helpful in determining the need for additional in office follow up.  
3. BIOTRONIK Home Monitoring® patients —who are followed remotely with office 
visits when needed —have been shown to have similar numbers of strokes, invasive 
procedures and deaths as patients followed with conventional in office follow ups.  
4. BIOTRONIK Home Monitoring® provides early detection of a rrhythmias.  
5. BIOTRONIK Home Monitoring® provides early detection of silent, asymptomatic 
arrhythmias.  
6. Automatic early detection of arrhythmias and device system anomalies by 
BIOTRONIK Home Monitoring® allows for earlier intervention than conventional in office 
follow ups.  
7. BIOTRONIK Home Monitoring® allows for improved access to patient device data 
compared to conventional in office follow ups since device interrogation is automatically 
scheduled at regular intervals.  
In current US market released BI OTRONIK devices, BIOTRONIK Home Monitoring® 
provides event and system information similar to what is currently available during office 
follow -up visits. The BIOTRONIK Home Monitoring® Quick View Summary Report , 
Figure 9, displays  rate trends and episode updates with parameters that are transmitted 
every 24 hours . These parameters include technical parameters (battery status, sensing 
amplitudes, and the percentage of noise per day) as well as physiological parameters 
(heart rate, he art rate variability, patient activity) and arrhythmia parameters (atrial 
burden, ventricular heart rate during atrial burd en, and the number of episodes) . 
  
Version 11 -Apr-2016  Page  14 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Figure 9: Quick View Summary for the BioMonitor 2  
 
 
 
 
  
Version 11 -Apr-2016  Page  15 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
2. STUDY DESIGN  
This mu lti-center, prospective, non -randomized post-market study is designed to 
evaluate the safety and feasibility of performing the BioMonitor 2 insertion procedure in  
an office setting. All subjects enrolled in the study will be implanted with a US market 
released BIOTRONIK BioMonitor 2. 
Potential subjects will be identified by the investigator from their general patient 
population and must have an approved indication for continuous arrhythmia monitoring 
with an ICM. Subjects will be consented within 30 days pr ior to the insertion procedure 
and will be screened to ensure they meet all of the inclusion and none of the exclusion 
criteria as outlined in Sections 3.1.3  and 3.1.4 . After eligibility is determined and written 
informed consent is obtained , subjects will be considered ‘provisionally enrolled’ until 
they undergo successful insertion , at which time they are considered fully enrolled . 
Subjects must undergo insertion wit hin 30 days  of provisional  enrollment. Subjects who 
are provisionally enrolled that  do not undergo successful insertion within 30 days  will be 
considered screen failures , unless the insertion was unsuccessful due to a protocol 
defined procedure -related adverse event or the insertion procedure was aborted after 
local anesthesia was applied. These  subjects will be considered fully enrolled and will 
be followed for 30 days to capture any adverse events  related to the insertion 
procedure. Device data and protoc ol-defined  adverse events will be collected from the 
date of the first insertion attempt and thereafter through 90 day post -insertion  for 
subjects with successful insertion procedures . 
Subjects who undergo successful insertion procedures  will be required t o complete an 
initial wound check visit 7 days (window -2, +7 days)  after the procedure  and a routine 
follow -up visit at 90 days (window -15, +30 days)  post-insertion . Subjects should be 
seen  in-office  for all study visits  to assess the BioMonitor 2 device  and assess for 
adverse events. For s ubjects with remote monitoring capabilities , a BIOTRONIK Home 
Monitoring® report  should be used  for the device data collected at any study visit; 
however, the BIOTRONIK Home Monitoring® data must be accompan ied with  an in-
office visit .  
Figure 10 provides an overview of the clinical study  design. Details of subject eligibility 
requirements are noted in Section 3.1 and details of other study specific procedures and 
data collection are noted in Section 3.2 and Section 4.  
  
Version 11 -Apr-2016  Page  16 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Figure 10: Study Design Flowchart  
ENROLLMENT
Identify Potential Subject
Will the subject undergo an insertion procedure with a 
qualifying BioMonitor 2 within the next 30 days?Subject is not 
a candidate.
Screen
Does subject satisfy the inclusion/exclusion criteria?
Enrollment Procedures
Subject provides written informed consent and 
enrollment data is collected. 
subject is provisionally enrolled
Insertion Procedure
Was the insertion procedure successful?
Study Evaluation
Subjects who are fully enrolled, but do not undergo successful 
insertion will be followed for 30 days to capture any adverse events 
related to the insertion procedure. 
For all other fully enrolled subjects, collect required data from the 
following post-insertion evaluations:
Scheduled wound check evaluation at 7 days (-2, +7 day 
window)  post-insertion and follow-up at 90 days (-15, +30 day 
window) post-insertion 
Interim follow-ups for AEs or device removalINSERTION
VISITSSubject is a 
screen failure.
Subject is a 
screen failure.YESNO 
NO 
YES
Was the insertion unsuccessful 
due to a protocol defined 
procedure-related complication?
-or-
Was the unsuccessful insertion 
procedure aborted after local 
anesthesia was applied?
Subject is fully enrolled
Collect required data during insertion.NO YES
NO 
YES
 
 
  
Version 11 -Apr-2016  Page  17 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
2.1 STUDY OBJECTIVES  
This study includes the assessment of one primary objective related to the safety of in -
office BioMonitor 2 insertions and several secondary objectives related to the 
associated safety and feasibility . Due to the sample size, th ere are no pre -specified 
hypotheses tested in this study.   
2.1.1  Primary Objective  1 
The purpose of primary objective 1 is to characterize all  insertion procedure -related 
adverse events  that require additional invasive intervention to resolve. All adverse 
events  that are considered insertion procedure -related by the investigator will be 
adjudicated by a Clinical Events Committee (CEC) for classification of the adverse 
event (as defined in Section 9). The results will b e summarized with respect to category  
and will include event details.   
2.1.2  Secondary Objective  1 
The purpose of secondary objective 1 is to characterize all insertion procedure -related 
adverse events  that are not included in the primary objective . The results  will be 
summarized with respect to category and will include event details.   
2.1.3  Secondary Objective  2 
The purpose of secondary objective 2 is to characterize the insertion procedure. This 
includes the specific device orientation  (as defined in Figure 3), final incision size, and 
total procedure duration . The results will be summarized.  
2.1.4  Secondary Objective  3 
The purpose of secondary objective 3 is to characterize device functionality p ost-
insertion . This will be achie ved by collecting R -wave amplitudes on the day of insertion  
and at any study  visit or through a BIOTRONIK Home Monitoring® report  if applicable.  
Long -term trends available through BIOTRONIK Home Monitoring® will also be used to 
characterize device function ality through the 90 -day study period.  The results will be 
summarized and statistically analyzed, where appropriate.  
2.1.5  Additional Data of Interest  
Additional information may be collected to characterize the study population, implanted 
system, insertion proce dure, and progress of the study. When available, the collected 
information may include baseline demographics, medical history, implanted system  
information , device removals , returned product analysis, and compliance. Specifically, 
data of interest may incl ude: 
 Baseline demographics, including age, gender, weight, height, New York Heart 
Association (NYHA) class, ejection fraction, and race and ethnicity (optional)  
 Medical history, including indication for device  
  
Version 11 -Apr-2016  Page  18 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
 Implanted device information , including date of insertion  and serial numbers for the 
BioMonitor 2 device  and accessories   
 Noise burden   
 Triggered sECGs  
 Investigator assessment of appropriate sECG classification  
 Resources used during the insertion procedure  
 Overall  physician satisfa ction and experienc e with in -office procedures  
 All other protocol -defined adverse events excluded from primary  objective 1  and 
secondary objective  1 
 Removal  experience , if applicable  
 Results from returned product analysis  
 Compliance to protocol requirements and study  visit s chedule  
When reporting medical history for most recent ejection fraction and the current NYHA 
class , details regarding the assessments must be obtained within 6 and 3 months prior 
to enrollment respectively . 
2.2 STUDY SIZE AND DURATION  
During this study, data will be gathered, analyzed, and reported to evaluate the safety 
and feasibility of the BioMonitor 2 in -office insertion procedure . It is anticipated that  75 
subjects will be implanted and followed through a 90 day post -insertion  at up to 7 US 
sites with up  to 20 subjects at each site .  
2.3 SAMPLE -SIZE ANALYSIS  
The study  is designed to limit the number of subjects involved while still exposing the 
device to a sufficiently large subject population in order to ensure a representative and 
statistically meaningful s ample.   
  
Version 11 -Apr-2016  Page  19 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Table 1 demonstrates the precision in estimating the primary objective 1 adverse event  
rate with the sample size of 75 subjects . 
Table 1: Precision in Estimating Adverse Event  Rates : Exact 95% Conf idence 
Intervals  
Number of  
Events  Rate  Confidence Intervals 
(CI) 
1 1.3%  (0.0%, 7.2%)  
2 2.7%  (0.3%, 9.3%)  
3 4.0%  (0.8%, 11.3%)  
4 5.3%  (1.5%, 13.1%)  
5 6.7% (2.2%, 14.9%)  
6 8.0%  (3.0%, 16.6%)  
7 9.3%  (3.8%, 18.3%)  
8 10.7%  (4.7%, 20.0%)  
9 12.0%  (5.6%, 21.6%)  
10 13.3%  (6.6%, 23.2%)  
20 26.7%  (17.1%, 38.1%)  
 
The sample size required to assess  primary objective 1 is based on an exact, point 
estimate and one-sided upper 95% confidence interval . The sample  size for primary 
objective  1 was calculated based on the following assumptions:  
The standard normal approximation to the 95% confidence interval associated with an 
estimate of a binomial parameter (p) is given by:  
 
95% Confidence Interval:      p   ±    1.96  [ p (1 – p) / n ] ½   
 
For example, if there were 4 adverse events  out of 75 cases, the observed adverse 
event  rate would be 5.3% and the exact binomial calculation would result in  a 95% CI of 
(1.5%, 13.1%). 
 
2.3.1  Replacement of Subjects  
A maximum loss to follow -up of 2% of the total sample size is estima ted. The attrition 
rate encompasses all cases of subject exits prior to study completion, and will include 
any subject exits. This includes death, device explants, subject directed withdrawals, 
physician -directed withdrawals, and loss of contact with the s ubject.  Subjects who are 
provisionally enrolled that do not undergo insertion and are considered screen failures 
are not included  in attrition . In order to ensure a sufficient population size for data 
analysis, subjects who exit prior to insertion or are d etermined to be screen failures may 
be replaced as long as enrollment is ongoing. This includes subjects who were 
determined  to be ineligible  for insertion  or withdrew from the study prior to the 
application of local anesthesia during the insertion procedu re. These subjects do not 
count toward the overall planned subject number of 75.  
  
Version 11 -Apr-2016  Page  20 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
2.4 DATA ANALYSES  
Descriptive statistics will be used to present and summarize the data collected in the 
clinical study. Frequency distributions and cross tabulations will be pres ented for 
discrete variables. Means, standard errors, and ranges will be presented for continuous 
variables.  
2.4.1  Objective  Analysis  
Primary objective 1 will be assessed  by performing an exact , point estimate and one -
sided upper 95% confidence interval for the rate of  insertion procedure -related adverse 
events  requiring invasive intervention within 90 days of insertion. All p-values of 0.05 or 
lower will be considered evidence of statistical significance.  
Secondary objective  1, which includes all other  procedur e-related  AEs that are excluded 
from primary objective 1 , will be summarized with respect to categorized AE rates with 
their associated, exact, 95% confidence interval.  
Other s econdary objectives , which include the characterization of  the insertion 
proced ure and device functionality,  will be analyzed quantitatively and statistically where 
appropriate. All available results will be categorized and summarized. With respect to 
device functionality, values will also be grouped by visit (enrollment, 90-day foll ow-up, 
and interim follow -ups as appropriate ). 
2.4.2  Trend Analyses  
The primary objective  is assessed at 90 days  post-insertion  using a point -estimate and 
one-sided upper 95% confidence interval. The Kaplan -Meier survival curve method will 
be used to estimate the adverse event rate at 90 days post -insertion procedure  if at 
least 1 event is  observed . Root causes for any failures, regardless of the incidence 
rates, will be investigated. Long -term device functionality trends may be collected and 
analyzed from availa ble BIOTRONIK Home Monitoring® reports from insertion through 
the 90 -day follow -up.  
2.4.3  Missing Data  
All possible steps will be taken to minimize missing data in the study. This includes but 
is not limited to monitoring of study forms for completeness and sup porting efforts to 
track and maintain contact with study  subjects during the follow -up period.  
The reasons for any missing data in the study will be documented. In cases of missing 
device data, BIOTRONIK Home Monitoring® will be used to impute the missing  data 
points. When available, missing data will be imputed with BIOTRONIK Home 
Monitoring® values obtained from the device on the day of a completed follow -up, target 
date of a missed follow -up, or the next closest day in the visit window.  
  
Version 11 -Apr-2016  Page  21 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
With respect to  the assessment  of the primary objective, only subjects who experience 
an adverse event associated with the insertion procedure that requires invasive 
intervention to resolve will be compared to subjects that complete the 90 -day follow -up. 
The secondary objective, which includes other AEs associated with the insertion  
procedure  excluded from the primary analyses, will be assessed  in a similar manner. 
There will be no imputation for these missing adverse event outcomes.  Home 
Monitoring® reports will be accept ed for device data to support the secondary objectives 
in the event that the subject is lost to follow -up. 
  
Version 11 -Apr-2016  Page  22 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
3. PROTOCOL REQUIREMENT S 
3.1 SUBJECT POPULATION  
The investigator is responsible for screening all potential subjects  and selecting those 
who are appropriate  for study inclusion. Potential subjects will be evaluated against the 
inclusion and  exclusion criteria described  below in Sections  3.1.3  and 3.1.4 . The 
subject s selected for participation should be from the investigator's general patient 
population according to the same inclusion  and exclusion criteria . 
3.1.1  Indications  
The BioMonitor  2 is an ICM that records subcutaneous ECG (sECG) and is indicated 
for: 
 Patients with clin ical syndromes or situations at increased risk of cardiac arrhythmias  
 Patients who experience transient symptoms that may suggest a cardiac arrhythmia  
 The device has not been tested for and it is not intended for pediatric use   
3.1.2  Contraindications  
There are no known contraindications for the insertion of the BioMonitor 2. However, the 
patient’s particular medical condition may dictate whether or not a subcutaneous, 
chronically inserted device can be tolerated.  
3.1.3  Inclusion Criteria  
To support the objectives of t his study , the inclusion criteria at the time of subject 
enrollment include the following requirements:  
 Indicated for continuous monitoring with an insertable cardiac monitor  
 Willing to be implanted in an office setting with only local anesthetic available  
 Able to understand the nature of the study and provide informed consent  
 Able and willing to complete all routine follow -up visits at the study site for the 
expected 90 -day follow -up 
 Able and willing to use a CardioMessenger® capable of communicating with the 
BioMonitor 2  
 Age greater than or equal to 18 years  
At the time of insertion, the following pre-procedure  criteria must be met for the subject 
to undergo insertion : 
 Most recent INR value (within 7 days) is less than 3.5  if currently  taking  warfarin  
 Abse nce of infection with no history of infection within the last 30 days  
 
  
Version 11 -Apr-2016  Page  23 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
3.1.4  Exclusion Criteria  
To support the objectives of this study , the exclusion criteria at the time of subject 
enrollment include the following requirements:  
 Compromised immune system or at high risk of developing an infection   
 Abnormal thoracic anatomy or scar tissue at the implant site that may adversely 
impact the insertion  procedure  
 Enrolled in any investigational cardiac device trial  
 Currently indicated for or implanted with a pacemaker , ICD device, or hemodynamic 
monitoring system  
 Currently implanted with an ICM or ILR  
 Life expectancy less than 6 months  
 Patients reporting pregnancy at the time of enrollment  
3.2 STUDY PROCEDURES  
Subjects will be fully enrolled at the time of insertion  of a B IOTRONIK BioMonitor 2 ICM. 
BIOTRONIK Home Monitoring® should be activated in  all subjects. All subjects must be 
seen in -office for all follow -up interva ls regardless of remote monitoring  activation , but 
the device data should  be provided via BIOTRONIK Home  Monitoring®. Device d ata 
from BIOTRONIK Home Monitoring® should be chosen from a transmission on or before 
the d ate of the in -office visit, no more than seven days prior to the date of visit . 
Additionally, subjects with unsuccessful insertion proc edures a s outlined in Section 
3.2.3  will be followed for a period of 30  days to capture any adverse events  related to 
the insertion procedure . At the end of the 30 -day safety period, a follow -up visit or 
phone call will be required to assess for adverse events.  
Study  Procedure Visits:  
 Enrollment  (subjects  are considered provisionally enrolled until undergoing  insertion ) 
 Insertion   
 Wound check visit 7 (window -2, +7)  days post -insertion  
 Routine follow -up evaluations at 90 (window -15, +3 0) days  post-insertion  
 Interim evaluations  
  
Version 11 -Apr-2016  Page  24 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Table 2 summarizes the visit assessment schedule.  
Table 2: Study Visit Assessment Schedule  
 Enrollment  Insertion1 Wound 
Check Visit2 90-day 
Follo w-up2 Interim 
Evaluation   
(if applicable)2,3 
Informed Consent 
(enrollment)  X     
Demographics and 
Medical History  X     
Implant Information  
with Device Evaluation   X4    
Device Evaluation    X X X 
Device Data Read Out     X5  
Triggered Events    X X X 
Adverse Event 
Assessment   X X X X 
Complete eCRF  X X X X X 
1Insertion  must be completed within 30 days of  provisional  enrollment/informed consent.  
2Subjects using BIOTRONIK Home Monitoring ® should provide  device data via  BIOTRONIK Home Monitoring ® for any study visit , 
but still must be seen in -office for AE assessment  
3Interim  follow -up information is collected as defined in 3.2.5 . 
4If the insertion procedure is unsuccessful due to a procedure -related adverse eve nt or is aborted after anesthesia is applied, the 
subject will  be followed for a period of 30 days to capture any adverse events related to the insertion procedure.   
5Detailed instructions provided in Appendix B.  
3.2.1  Study Pre -screening  
Prior to enrollment, t he patient’s medical history must be reviewed in order to ensure 
they are an appropriate candidate for the study . Subjects taking any oral anticoagulant 
(OAC ) may be asked to hold their medication prior to the insertion procedure at the 
discretion of the i mplanting physician. In addition, all patients must satisfy the study  
inclusion and exclusion criteria prior to enrollment, including being a candidate for a 
BIOTRONIK BioMonitor 2 ICM.  
3.2.2  Enrollment Visit  
If the patient has been determined to be eligible for  the study, informed consent must be 
obtained from the patient prior to initiating any study related procedures. The consent 
process, including discussion of the study, should be documented in the patient’s 
medical  or study  record s.  
  
Version 11 -Apr-2016  Page  25 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
The following data col lection and reporting procedures are performed at enrollment:  
 Obtain Informed Consent  
 Collect subject demographics (gender, height, weight, etc.)  
 Medical history of subject, including device implant indications  
 Complete all required eCRFs  
3.2.3  Insertion  
Inserti on will take place in an office setting. The insertion  may be completed on the 
same day as informed consent or within 30  days after.  If the subject is taking OACs at 
the time of enrollment, the implanting physician will decide how long they ma y need to 
hold their medication  and the subject may not be able to undergo the BioMonitor 2 
insertion on the same day.  BioMonitor  2 will be inserted  on the left chest  side as 
described in Section  1.4.2 . The physician perform ing the insertion will  also determine 
the optimal device position  for each subject , as described in  Figure 3. 
Subjects are considered provisionally enrolled until they are successfully implanted with 
the BioMonitor  2, at which time they are considered fully enrolled. Subjects who are 
provisionally enrolled that do not undergo successful insertion procedures within 30 
days will be considered screen failures , unless the insertion was unsuccessful due to a 
protocol def ined procedure -related adverse event  or the insertion procedure was 
aborted after local anesthesia was applied . These  subjects will be considered fully 
enrolled, included in the intention -to-treat (ITT) population , and followed for 30 days 
post-insertion t o capture any adverse events related to the insertion procedure. At the 
end of the 30 -day safety period, a follow -up visit or phone call will be required to assess 
for adverse events.  
The following data collection and reporting procedures are performed at insertion : 
1. Confirm the subject meets the pre -procedure inclusion criteria:  
 Most recent INR value (within 7 days) is  less than 3.5  if currently taking warfarin  
 Absence of infection with no history of infection within the last 30 days  
2. Collect insertion info rmation.  
 Date of procedure  
 Method  and approach including : 
o Device orientation ( as described in Figure 3) 
o Final incision size  (measured with a suitable tool ) 
o Insertion procedure time  (measured from incision to last s uture)  
 Procedure s uccess  
3. Collect device serial numbers for the BioMonitor 2 , CardioMess enger®, and Remote 
Assistant . 
  
Version 11 -Apr-2016  Page  26 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
4. Record initial R -wave amplitudes  as outlined in  Appendix B . 
5. Record any insertion procedure -related and device -related adverse events  during  
insertion  and complete an Adverse Event eCR F. Insertion procedure -related 
adverse events should be reported even if the insertion  attempt is unsuccessful . 
6. Program BioMonitor 2  parameters to best suit the needs of the subject . 
7. Interrogate and print the fin al programmed parameters.  
8. Complete all required eCRFs.  
3.2.4  Wound Check Visit and 90 -day Follow -up 
Subjects will undergo an assessment of their device at a wound check visit  7 days  post-
insertion (window  -2, +7  days) and a 90 -day follow -up after insertion  (window -15, +30 
days ). BIOTRONIK Home Monitoring® transmissions should  be used  for the device data 
at any follow -up, including the wound check and 90-day visit; however, an in-office visit 
to support an AE assessment and other protocol requirements  will still be required . 
Device d ata from BIOTRONIK Home Monitoring® should be chosen from a transmission 
on or before the d ate of the in -office visit, no more than seven days prior to the date of 
visit. 
Each site Principal Investigator (PI) will be trained to identif y and schedule follow -ups to 
meet the required expectation. Additionally, the Electronic Data Capture (EDC) system 
will provide assistance in identifying properly scheduled follow -up visits  according to this 
protocol.  
The following study procedures are per formed at the wound check visit and 90 -day in -
office follow -up: 
1. Obtain BIOTRONIK Home Monitoring® Cardio Report from a transmission on or 
before the d ate of the in -office visit, and within  seven days prior to the date of visit  if 
available.  
2. Activate the Re mote Assistant  and wait approximately 2 minute s.  
3. Interrogate the BioMonitor 2 and print initial programmed parameters and view 
stored diagnostic data.  
4. Record the daily average R-wave amplitudes and corresponding date through 
BIOTRONIK Home Monitoring®. If BIOTRONIK Home Monitoring® is not available, 
record the R -wave amplitudes  as described in Appendix B.  
5. Record the daily average noise percentage  through BIOTRONIK Home Monitoring®. 
If BIOTRONIK Home Monitoring® is not available, record the noise percentage  as 
described in Appendix B . 
6. If there have been  any triggered events or alerts since the subject was last seen , not 
including the recording triggered at the visit : 
 Evaluate cause of patient triggers.  
  
Version 11 -Apr-2016  Page  27 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
 For non -patient triggers, determine if the rhythm associ ated with the trigger 
classification is able to be confirmed, when possible, using methods such as 
surface ECG verification, symptoms indicative of rhythm, etc. If any triggers were 
suspected to be inappropriate, document the suspected reason (s). 
7. Determine  if there have been any adverse events (as defined in Section  9). If any 
are recorded, complete an Adverse Event eCRF.  
8. Program other parameters to best suit the needs of the subject . 
9. At the 90 -day follow -up visit perform a device data “Read out” to print and store the 
BioMonitor 2 data  as described in Appendix B . 
10. Interrogate and print the final programmed parameters . 
11. Review and complete the appropriate eCRFs . 
3.2.5  Interim Follow -ups and System Revisions  
Interim follow -ups may occur anytime during the study, at the request of the  investigator 
or subject, as a result of a triggered sECG or BIOTRONIK Home Monitoring® alert, etc . 
Anytime a subject’s device is interrogated for any reason during the 90 -day study 
period, data  should be collected (as outlined in Section 3.2.4 ) and an int erim Follow -up 
eCRF completed. In the event of a subject evaluation to assess for  a protocol -defined 
adverse event, in which a device interrogation does not occur, an interim Follow -up 
eCRF does  not need to be completed, but adverse event  data should be captured on 
the Adverse Event  eCRF. Other hospital or clinic visits that are unrelated to the device  
or insertion procedure  are not required to be collected.   
Any system revision that is  performed  after successful insertion of the device but prior to 
the 90 -day follow -up has to be documented in the study. A system revision is defined as 
any reposition or removal of the original inserted BioMonitor 2. In the event of a system 
revision, a System Revi sion eCRF is required as well as the following data : 
 Reason for reposition  or removal  
 Date of reposition or removal  
 Type of revision   
 Location of revision (clinic, hospital, office, etc.)  
 Outcome of revision (including type of replacement  and device manufa cturer , if 
applicable)  
In the event of a reposition , the new device orientation will also be collected.  
 
  
Version 11 -Apr-2016  Page  28 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
4. DATA COLLECTION  
4.1 ELECTRONIC DATA CAPTURE (EDC)  
MedNet Solutions Incorporated is a privately held company that specializes in web -
based clinical data ma nagement technology. MedNet will host the EDC system and 
provide a secure environment that is accessible to authorized individuals through the 
internet. BIOTRONIK will implement a study  specific configuration using this software to 
meet the data collection  requirements of the protocol. The EDC system is 21 CFR Part 
11 compliant and is the platform for electronic Case Report Form (eCRF) data entry, 
clinical data discrepancy resolution, and access to reports for BIOTRONIK, specified 
study sites, and any other  parties authorized by BIOTRONIK.  
4.2 ELECTRONIC CASE REPORT FORMS (ECRF S) 
Original data will be collected at each study site and recorded into the EDC system . 
BIOTRONIK will audit source data and monitor completed investigator locked eCRFs.  
The investigator will be required to use an electronic signature to approve the content of 
the data reported in the eCRFs.  
Information from electronically delivered source data (e.g. programmers) will be 
captured and stored in a validated environment.  
Subject follow -up is required for all subjects fully enrolled in this clinical study . The 
required follow -up visit dates are based on BioMonitor 2 insertion date, and are to be 
used for the calculation of the dates of the routine follow -up schedule. The following 
eCRFs will be  available in the EDC system:  
 Informed Consent  
 Informed Consent Update  
 Enrollment  
 Insertion   
 Wound Check Visit ( -2, +7 day  window ) 
 90-day Follow -up (-15 , +30 day  window)  
 Interim Follow -up  
 Adverse Event  
 System Revision  
 Study  Exit 
 Protocol Noncompliance  
 Data Clarification  
  
Version 11 -Apr-2016  Page  29 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
4.3 DATA CLARIFICATION /DATA QUALITY CONTROL  
BIOTRONIK will review study  data. At any time, reports can be generated on data 
completion and missing data for each study site. An EDC system will be used to track 
received and expected follow -up d ata and eCRFs for each participant. This system 
provides the capability to monitor the status, volume, and disposition of data as well as 
to identify data completed, due, overdue, and backlogged. In addition, all study  data will 
undergo automatic edit and plausibility checks, which provide information to the study 
sites to help improve and maintain data quality control procedures designed to detect 
inaccuracies and inconsistencies.  
To ensure protocol compliance at all participating study sites, BIOTRONIK m onitors will 
conduct monitoring visits (see Section  7).  
To ensure compliance with federal regulations, internal policies and procedures, and the 
study  protocol, the EDC vendor will routinely  be monitored and/or  audited by 
BIOTRONIK or a BIOTRONIK representative  as required by BIOTRONIK standard 
operating procedures (SOPs) . 
4.4 SUBJECT RETENTION  
Due to the relatively small population size, subject attrition is not considered to be a 
challenge. A maximum loss to follo w-up of  2% of the total sample size is estimated . 
BIOTRONIK will provide additional tools to the sites in an effort to minimize the number 
of subjects that are lost to follow -up. The EDC system includes an overview of each 
subject’s follow -up schedule, inc luding the windows for each follow -up. The EDC 
system also provides a subject follow -up tool in the form of a Follow -up Compliance 
Detail  Report. This report allows research personnel to become alerted to and track all 
study  subjects that should be schedul ed for upcoming follow -ups.  
4.5 SUBJECT DATA CONFIDENTIALITY  
All information sent to BIOTRONIK  pertaining to each subject will be kept confidential at 
BIOTRONIK  and is subject to FDA audit. Source documents used to support study 
objectives  adjudication by the  CEC will have all confidential subject identifiers redacted 
prior to being provided to the CEC . Reports submitted to the physician and publications 
of study  results will not make any reference to subject names.  
In order to verify the study  data and ensure  study  integrity, monitors from BIOTRONIK, 
the FDA, and the reviewing Institutional Review Board (IRB) may review and/or copy 
the study  records . 
 
 
  
Version 11 -Apr-2016  Page  30 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
5. RISKS AND RISK MINIM ALIZATION  
All devices included in this study  are legally marketed and being prescribed by  
physicians according to FDA approved indications for use.  
As with any implantable device, there are always potential risks that accompany the 
device. The following list provides the potential risks that may occur with the use or 
insertion of the BioMonito r 2: 
 Device failure  
 Device migration  
 Device rejection phenomena (including local tissue reaction)  
 Excessive bleeding  
 Fluid accumulation within the device pocket  
 Hematoma  
 Infection  
 Pocket pain  
 Skin erosion  
These risks can be minimized through use of strict aseptic technique, compliance with 
the study  protocol and technical insertion  procedures, adherence to the guidelines for 
selection of subjects, close monitoring of the subject’s physiologic status during 
insertion  and follow -up procedures, and by promptly  supplying BIOTRONIK with all 
pertinent information required by this protocol.  
As excessive bleeding is of particular concern with in -office procedures, subjects taking 
warfarin or any other OAC  may be asked to hold their medication prior to the insertion  
procedure at the discretion of the implanting physician . 
BIOTRONIK foresees no additional risks associated with this study  beyond those stated 
in the labeling for device . 
 
  
Version 11 -Apr-2016  Page  31 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
6. STUDY  ORGANIZATION  
6.6 SPONSOR  
BIOTRONIK  is the "sponsor" of the BioInsight Study .  A " sponsor" is defined as an entity 
that initiates but does not conduct a study .  BIOTRONIK’ S responsibility as the clinical 
study sponsor is to ensure protocol and regulatory compliance through proper 
monitoring of the study .  BIOTRONIK  is required to ensure  that the device is used under 
the immediate direction of an investigator.  As the investigator, the physician is 
responsible for conducting the study in accordance with the signed agreement, the 
study  protocol, applicable laws, FDA regulations, and any co nditions of approval 
imposed by the reviewing IRB.   The primary investigator must also accept responsibility 
for all aspects of the study including the actions of any co -investigators participating in 
the study at the study  site. 
6.7 CLINICAL EVENTS COMMITTEE   
A Clinical Events Committee (CEC) consisting of at least 3 independent 
electrophysiologists will be established to review and adjudicate adverse events that 
occur during the study . The CEC will be blinded to the clinical study  site and subject 
identity, and to minimize bias, members will not participate as investigators. The CEC 
will create a study  specific charter defining the adverse event adjudication process, 
specifically detailing review guidelines along with appropriate response timelines.  
All proto col defined adverse events (see  Section 9.1) will be adjudicated by the CEC . 
The CEC  will classify the adverse event and  indicate whether the adverse event is 
related, possibly related, not related, or has an unknown relation t o the BioMonitor 2 
insertion procedure. The CEC will also  have the responsibility to adjudicate the type of 
adverse event (insertion procedure -related, device -related, and non -procedure non -
system related)  and specific category (Section 9.1).  
  
Version 11 -Apr-2016  Page  32 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
7. STUDY  MONITORING  
7.1 SUMMARY  
BIOTRONIK’s responsibility as the clinica l study  sponsor is to ensure protocol and 
regulatory compliance through proper monitoring of the study . BIOTRONIK requires IRB 
review and a subject Informed Consent Form for  all after -market research. Monitoring 
may be conducted on -site at the study site or remotely by BIOTRONIK monitors.  
Through on -site or centralized monitoring, BIOTRONIK will assess the site’s 
performance in the following areas:  
 Verification that informe d consent was obtained  
 Adherence to protocol eligibility criteria and requirements  
 Documentation of performed  procedures and assessments related to:  
 Study objective s 
 Protocol required safety assessments  
 Evaluating, documenting, and reporting subject death s and withdrawals, 
especially when a withdrawal may be related to an adverse event.  
 Investigator oversight and delegation of authority to study personnel  
 Verification of study -specific required documentation  
 Conduct and documentation of procedures essentia l to trial integrity  
 Adherence to the applicable FDA regulations regarding the obligations of the 
investigator and maintenance of records.  
As the investigator, the physician is responsible for conducting the study  in accordance 
with the signed agreement, t he study protocol, applicable laws, FDA regulations, and 
any conditions of approval imposed by the reviewing IRB. The principal investigator 
must also accept responsibility for all aspects of the study  including the actions of any 
sub-investigators partici pating in the study  at the study site.  
7.2 STUDY  MONITORS  
Study monitors are trained, qualified, and designated by BIOTRONIK management to 
oversee the progress of a study  at the study  site. Additional monitors may be appointed 
as necessary.  
  
Version 11 -Apr-2016  Page  33 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
The address to sub mit study  information to BIOTRONIK  is: 
BIOTRONIK,  Inc. 
Attn: BioInsight Study  
Clinical Studies Department  
6024 Jean Road  
Lake Oswego, Oregon 97035  
Study  information may also be submitted by fax to:  (800) 723 -9220  
For study assistance, call: (800) 547 -0394  
For technical a ssistance 24 hours a day, call: (800) 547 -0394  
7.3 MONITORING VISITS 
A monitor will conduct monitoring visits at study sites in accordance with the Monitoring 
Plan. Sites are required to support these visits and the study monitoring effort. On -site 
monitoring visits will also provide an assessment of the continued acceptability of the 
facilities to continue participation in the study .  
7.4 CENTRALIZED MONITORING  
Centralized monitoring will be conducted throughout the course of the study in 
accordanc e with the Monitoring Plan. Some examples of data that may be monitored 
remotely include : informed consent forms , insertion  and device data , and adverse 
events reported in the EDC system. Sites are required to support centralized monitoring 
by providing so urce documents to BIOTRONIK in order to source data verify data 
reported in the EDC system and resolving queries in a timely manner.  
 
  
Version 11 -Apr-2016  Page  34 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
8. STUDY COMPLETION  
BIOTRONIK will notify the study site upon completion or termination of the study or 
investigator’s parti cipation in the clinical study. At BIOTRONIK’s request, an investigator 
will return any devices, equipment and pertinent information in their possession.  
BIOTRONIK  will provide a final report to each study site. The investigator must retain 
records relate d to the study for a period of 2 years after the study  is completed.  
9. ADVERSE EVENTS  
The rate of insertion procedure -related adverse events (AEs) within 90 days post -
insertion that require additional invasive intervention to resolve will be assessed . 
Additi onal data will be collected on the safety and feasibility of in -office insertion 
procedures.  
An AE is defined as any unfavorable and unintended event that occurs during the 
course of the study. The investigator will be required to assess and classify the type of 
each reported adverse event  as insertion procedure -related , device -related,  or non-
procedure  non-system  related. Only adverse events occurring in fully enrolled subjects 
on or after the date of insertion through the duration of the study will be col lected. If the 
insertion procedure is unsuccessful due to a procedure -related adverse event or is 
aborted after anesthesia is applied, the subject will be followed for a period of 30  days 
to capture any additional adverse events  related to the insertion pr ocedure.  
The study site should report each adverse event via an Adverse Event eCRF and 
provide a copy of the IRB adverse event notification to BIOTRONIK.  
9.1 REPORTABLE ADVERSE EVENTS  
All insertion procedure -related, device -related  and non -procedure non -syste m related  
AEs will be reported. The following AEs  categories, sorted by type,  will be reported. The 
types  listed below are general classifications for site reporting purposes. Detailed 
information for specific categories  is located in Appendix A. Final categories will be 
determined by the CEC. The CEC charter may include alternate classifications for some 
adverse events.  
9.1.1  Insertion Procedure -Related Adverse E vents  
The AE type will be classified as procedure -related if any one of the following occurs  as 
a res ult of the insertion  procedure:  
 Device damage  
 Excessive bleeding  
 Fluid accumulation within the device pocket  
 Hematoma  
  
Version 11 -Apr-2016  Page  35 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
 Inability to create pocket  
 Non-healing pocket dehiscence requiring intervention  
 Pocket pain 
 Primary infection  
 Superficial infection  
 Surro unding tissue damage  
9.1.2  Device -Related Adverse Events  
The AE type will be classified as device -related if any one of the following occur:  
 Device failure  
 Device migration  
 Device protrusion  
 Device rejection phenomena  
 Skin erosion  
9.1.3  Non-Procedure Non -System Relat ed Adverse Events  
The A E type will be classified as non -procedure non -system related if any of the 
following occur and require device removal : 
 Secondary infection  
 Other non -elective intervention  
9.2 ANALYSIS OF THE OBJECTIVES  
All protocol defined AEs included in the primary and secondary objective analysis will be 
adjudicated by the Clinical Events Committee (CEC) (see Section 2.1). For each AE, 
the CEC will classify  the relatedness to the insertion procedure  as not related, related, 
possibly related, or unknow n. The CEC will also have the responsibility to adjudicate the 
type (insertion procedure -related, device -related, or non -procedure non -system related) 
as well as the specific category  of each reported AE (see Section 9.1).   
In assessment of the primary objective , the estimate of AE rates will be based on the 
number of subjects with at least one AE adjudicate d as related  to the insertion 
procedure  as a proportion of total subjects. Events with a final  AE adjudica tion of 
possibly related, not related or unknown  relatedness classification will not contribute to 
or be included in the assessment of the primary objective . AEs related to the insertion 
procedure  that require additional invasive intervention to resolve  are included in primary 
objective 1. The same rules will be used for purposes of Kaplan -Meier survival 
analyses, described in Section 2.4.2 .  
  
Version 11 -Apr-2016  Page  36 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Secondary objective 1, which includes AEs that were excluded from primary objective 1 
through  90 days  post-insertion , will also be summarized as AE rates along with their 
associated, exact 95% confidence intervals.  
9.3 ADVERSE EVENTS FOR THE ANALYSIS OF THE PRIMARY AND 
SECONDARY OBJECTIVE S 
9.3.1  Adverse Events for t he Analysis of Primary Objective  1 
If any of the following invasive actions occur in order to resolve an above listed insertion 
procedure  AE, the AE will be included in the primary objective  analysis:  
 Device  removed  
 Device  replaced  
 Device  surgically repositioned  
 Other surgery performed related to the device or primary insertion procedure  
Subject deaths as a result of a  BioMonitor 2 insertion procedure -related AE will be 
included in the primary objective  analysis.  Additionally, an AE that requires a transfer to 
a hospital facility  during the i nitial in -office insertion procedure to resolve the AE will be 
included in the primary objective analysis.  
Primary objective  1 will exclude adverse events that do not meet these criteria . 
9.3.2  Adverse Events for the Analysis of Secondary Objective  1 
All inserti on procedure -related AEs excluded from primary objective  1 are included in 
secondary objective  1 analysis . 
9.4 ADVERSE EVENT REPORTING  
The AEs that an IRB considers reportable are dependent on the particular IRB. To avoid 
underreporting, BIOTRONIK recommends t hat, at a minimum, the investigator reports 
insertion procedure -related  and device -related AEs, as well as protocol -defined non -
procedure non -system related AEs,  that occur during the BioInsight  Study  to 
BIOTRONIK and the IRB.  
The study site will report th e AE on the Adverse Event eCRF. Additionally, study  sites 
may report AEs through MedWatch, FDA’s adverse event reporting tool for market -
released devices. As defined in BIOTRONIK’s internal procedures, AEs may be 
reported by BIOTRONIK through manufacturer’ s MedWatch reports.  
  
Version 11 -Apr-2016  Page  37 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
10. OTHER GENERAL INFORM ATION  
10.1 PROTOCOL COMPLIANCE  
The investigator is responsible for conducting the study in accordance with the signed 
agreement, the study  protocol, applicable laws, and any conditions of approval imposed 
by the reviewing  IRB. The investigator shall notify BIOTRONIK and the reviewing IRB in 
writing no later than 5 working days after any significant deviation from the study plan to 
protect the life or physical well -being of a subject in an emergency. Except in such 
emergenc y, prior approval by BIOTRONIK is required for significant deviations from the 
study plan.  
BIOTRONIK categorizes protocol noncompliance instances as either violations or 
deviations. Both protocol violations and deviations will be reported during interim 
reports.  
10.1.1  Protocol Violations  
Protocol violations are defined as instances where the protocol requirements and/or 
regulatory guidelines were not followed, and are generally more serious in nature. 
Protocol violations are considered to potentially affect the scientific soundness of the 
plan and/or the rights, safety, or welfare of subjects. Protocol violations include, but are 
not limited to:  
 Failure to obtain consent  
 Subject inclusion/exclusion violations and protocol requirement violations that affect 
the pr imary objectives of the study design  
These violations will be reported in accordance with applicable regulatory timelines and 
the site must notify the reviewing IRB  per the IRB ’s reporting requirements. The site 
should  provide a copy of the IRB  protocol no ncompliance notification (as applicable) to 
BIOTRONIK. Protocol violations must also be reported to BIOTRONIK via Protocol 
Noncompliance eCRFs.  
10.1.2  Protocol Deviations  
Protocol deviations are deviations from the requirements of the protocol in such a 
manner wh ereby data is unusable or not available. Protocol deviations are less serious 
in nature . The site should report protocol deviations of required per the IRB of record. 
Protocol deviations include, but are not limited to:  
 Procedure not performed within the a llowed follow -up window  
 Required data not obtained  
The site must report protocol deviations to BIOTRONIK via Protocol Noncompliance 
eCRFs. Both protocol deviations and violations will be reported in interim  reports.  
  
Version 11 -Apr-2016  Page  38 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
10.2 STUDY EXITS 
Once a subject is enrolled a nd successfully undergoes insertion , every effort should be 
made to continue to follow the subject in the study. However, it is inevitable that some 
subjects will decline to participate further, change geographic location, or become non -
compliant with the visit schedule.   
10.2.1  Screen Failures  
Screen failures, as defined in Section 3.2.3 , will be exited in the EDC system. The 
reason and date of withdrawal will be obtained and a Study  Exit eCRF  will be 
completed . 
10.2.2  Unsuccessful I nsertion  Procedures  
Subjects with unsuccessful insertion procedures, as defined in Section 3.2.3 , will be 
followed for 30 days post -insertion to capture any complications related to the insertion 
procedure and then will  be exited. The reason and date of withdrawal will be obtained 
and a Study  Exit eCRF  will be completed .  
10.2.3  Withdrawal of Consent  
If consent is withdrawn, the reason and date of withdrawal will be obtained and a Study  
Exit eCRF  will be completed . 
10.2.4  Subject Dea th  
In the event of subject death during study  participation, personnel at the study site are 
asked to notify BIOTRONIK as soon as possible by completing a  Study  Exit eCRF. If 
subject death was associated with an adverse event, an Adverse Event eCRF will a lso 
be required.  
The following information should be reported for any subject death : 
 Subject records such as a death certificate , death report signed by the investigator , 
or other relevant medical records  that include  the following details : 
 Date of death  
 Place death occurred  
 Immediate cause of death  
 Statement w hether death was device or insertion procedure -related  
Whenever possible, devices that are removed  should  be returned to BIOTRONIK for 
analysis.  
  
Version 11 -Apr-2016  Page  39 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
10.2.5  BioMonitor 2 Removal  
Any subject who has the BioMonito r 2 ICM removed  during the follow -up will be 
withdrawn from the study . If the BioMonitor  2 is replaced with another BioMonitor  2, the 
subject  will not continue participation in the study.  A Study Exit and System Revision  
eCRF should only be completed after  documentation of the device  removal  or 
replacement procedure  is available (see Section  3.2.5 ).  
Whenever possible, devices that are removed  must be returned to BIOTRONIK for 
analysis.  
10.2.6   Lost to Follow -up 
Subjects lost to follow -up are those for whom contact is lost despite the investigator’s 
best efforts to locate the subject. Study sites should attempt to contact these subjects in 
order to maintain study visit compliance and all contact attempts should be 
documented. At a minim um, the site should make and document two attempts to 
contact the subject by phone and one attempt by certified mail.  
In the event the subject cannot be contacted using the above methods, the subject 
should be exited from the study by completing a Study Exit eCRF.  BIOTRONIK Home 
Monitoring® reports will be accepted for device data to support the secondary objective s 
in the event that the subject is lost to follow -up. 
10.2.7  Study Participation Complete  
All subjects who undergo successful insertion procedures are e xpected to be followed 
for 90 days  post-insertion  (window -15, +30 days) . After a subject completes their final 
routine visit in this time interval, their study participation is complete and the subject 
should be exited from the study  by completing a Study  Exit eCRF.  
10.3 INFORMED CONSENT  
Prior to the subject’s participation in the study , informed consent is required from all 
subjects. Informed consent should be obtained in accordance with the FDA regulations 
(21CFR, Part 50). The investigator is required to inf orm BI OTRONIK and the reviewing 
IRB within 5 days if any subject was not appropriately consented to participate in the 
study . In order to assist with the consent process, BIOTRONIK will provide a template 
subject consent form to study  sites participating i n the study . 
10.4 IRB  APPROVAL  
IRB approval is required from each institution prior to participation in this post-market 
study . Subject enrollment may not begin until the IRB and BIOTRONIK have granted 
approval for the study site. IRB approval is also required throughout the duration of this 
clinical study . If IRB approval is withdrawn, BIOTRONIK must be notified within 5 
working days.  
  
Version 11 -Apr-2016  Page  40 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
10.5 OTHER INSTITUTIONS AND PHYSICIANS  
This post -market study  is not transferable to other institutions attended by the 
investigator unless prior approval is obtained from both BIOTRONIK and the 
appropriate IRB. Additional study sites may be included in this study but may not 
exceed the limits set by the protocol . Only approved investigators are authorized to 
participate in the study. H owever, there are certain situations where an investigator 
might not be immediately available to provide the necessary medical care for a subject 
enrolled in this study  (e.g. when a subject goes to the emergency room for medical 
treatment). In these instan ces a protocol deviation will not be issued and all available 
data will be utilized. In any such situations, the IRB and the investigator must continue 
to provide oversight for that subject’s medical care and rights as a research subject.  
  
Version 11 -Apr-2016  Page  41 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
11. RECORDS AND REPOR TS 
11.1 INVESTIGATOR RECORDS  
Investigators are required to maintain on file the following accurate, complete and 
current records relating to this study : 
 All correspondence relating to the study  with another investigator, an IRB, 
BIOTRONIK, a monitor, or the FDA , or any other regulatory authority. (e.g., a letter 
sent from the investigator to t he IRB ). 
 A copy of the study  protocol  
 Signed investigator or research agreement  
 Signed Financial Disclosure Form  
 A copy of the IRB  letter approving the research study  
 A cop y of the IRB approved subject Informed Consent Form  
 All documentation, including:  
 a copy of the signed subject consent form  
 all supporting documentation for data entered into the EDC system  
 records of any adverse device effect, including supporting documen tation  
 records pertaining to subject deaths during the study  
 documentation and rationale for any deviations from the clinical protocol  
 any other records required by BIOTRONIK  
 records of device disposition  
11.2 INVESTIGATOR REPORTS  
Investigators are required to prepare and submit to BIOTRONIK the following complete, 
accurate, and timely reports on this study  when necessary:  
 Notification of a subject death during the study  
 Notification of the withdrawal of IRB approval  
 Annual progress reports prepared for the IRB  
 Notification of any deviations from the study  plan 
 Notification that an informed consent was not obtained from the subject  
 Final summary report prepared for the IRB  
 Any other information upon the request of an IRB, FDA, or BIOTRONIK  
  
Version 11 -Apr-2016  Page  42 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Table 3 outlines the responsibilities, including time constraints, for submitting the above 
reports.  
Table 3: Investigator Reporting Responsibilities  
Type of Report  Report to 
BIOTRONIK  Report to IRB  Time Constra ints of Notification  
Subject Death During 
Study  Required  Required  BIOTRONIK as soon as possible and as 
required by reviewing IRB  
Subject Withdrawal  Required  IRB 
Dependent  Within 5 working days  
Withdrawal of IRB  
Approval  Required  Required  Within 5 workin g days  
Progress Report  Required  Required  Submitted not less often than yearly  
Significant Deviations from 
Protocol  Required  Required  Within 5 working days after emergency 
to protect life or physical well -being of 
subject, otherwise prior approval by 
BIOT RONIK is required  
Informed Consent Not 
Obtained  Required  Required  As soon as possible after discovery  and 
no more than 5 working days  
11.3 SPONSOR RECORDS  
BIOTRONIK will maintain the following records:  
 All correspondence that pertains to the study  with the in vestigator(s), IRB, and FDA  
 Investigator agreements, financial disclosures, and current curriculum vitae  
 Name and address of each investigator and each IRB that is involved with the study  
 Adverse events and complaints  
 Adverse device effects  
 Electronic Case Report Form data 
 Clinical study  plan and report of prior investigations  
 Monitoring reports  
 Clinical progress reports  
  
Version 11 -Apr-2016  Page  43 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Table 4 outlines the responsibilities, including time constraints, for sponsor reports.  
Table 4: Sponsor Reporting Responsibilities  
Type of Report  Prepared by  
BIOTRONIK for  Time Constraints  
of Notification  
Withdrawal of IRB Approval  All reviewing IRBs and 
participating investigators  Notification w ithin 5 working days of 
receipt of notice of withdrawal of 
approval  
Progress Report  All reviewing IRBs  A progress report will be submitted at 
least annually  
Recall and Disposition  FDA, all reviewing IRBs  Notification within 30 working days and 
will include the reasons for any requ est 
that an investigator return, repair or 
otherwise dispose of any devices.  
Final Report  All reviewing IRBs and 
participating investigators  Notification within  30 working days of 
the completion or termination of the 
study . A final report will be submitte d 
within 6 months after completion or 
termination of the study . 
  
Version 11 -Apr-2016  Page  44 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
12. REFERENCES  
[1] Pürerfellner H, et al. Miniaturized Reveal LINQ insertable cardiac monitoring system: 
First-in-human experience . Heart Rhythm  2015;12(6) :1113 -9. 
 
[2] Mittal S, et al. Safety Pr oﬁle of a Miniaturized Insertable Cardiac  Monitor: Results 
from Two Prospective Trials . Pacing and Clinical Electrophysiology  2015 ;38(12):1464 -9. 
 
[3] Pachulski R , et al. Implant Evaluation of an Insertable Cardiac Monitor Outside the 
Electrophysiology Lab  Setting . PLoS ONE  2013;8(e71544):1 -6. 
 
[4] Pakarien S, et al. Short -term implantation -related complications of cardiac rhythm 
management device therapy: a retrospective single -centre 1 -year survey. Europace 
2010;5:907 -25. 
 
[5] Poole JE, et al. Complicatio n rates associated with pacemaker or implantable 
cardioverter -defibrillator generator replacements and upgrade procedures: results from 
the REPLACE registry.  Circulation  2010;  122(16):1553 -61. 
 
[6] Hancox JG, et al. The Safety of Office -Based Surgery :  
Review of Recent Literature From Several Disciplines . Arch Dermatology  2004; 
140(11):1379 -82. 
 
  
Version 11 -Apr-2016  Page  45 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
APPENDIX A: DEFINITION OF TERM S 
AE – Adverse Event  
AF – Atrial Fibrillation  
CEC  – Clinical Events Committee  
CFR – Code of Federal Regulations  
Device Damage – Visible damage to the antenna or device body or mechanical 
malfunction that leads to the inability of the device to correctly sense the heart  signals . 
Device Failure  – Inability of the device to correctly sense the heart  signals , not 
attributable to a mechanica l malfunction  that remains unresolved despite 
reprogramming and/or repositioning.  
Device Migration – Visual , radiographic , electrical or electrocardiographic evidence of 
device displacement from the original implant site or electrode displacement that 
adve rsely affects device performance or subject health.  
Device Protrusion  – Device or antenna perforation through the skin that is not a result 
of skin erosion.  
Device Rejection Phenomena  – Reaction to device materials; includes local tissue 
reaction  and meta l sensitivity . 
eCRF  – Electronic Case Report Form  
EDC  – Electronic Data Capture system  
Excessive Bleeding  – Bleeding during the insertion procedure that cannot be stopped 
by applying pressure alone . 
FIT – Fast Insertion Tool  
Fluid Accumulation within the D evice Pocket - Fluid swelling within the insertion site 
that is not related to infection or considered to be a hematoma, which  requires surgical 
intervention to resolve.  
Hematoma – An accumulation or  persistent swelling of blood that requires evacuation, 
drainage, post -insertion hospitalization, or blood transfusion.  
ICD – Implantable Cardioverter Defibrillator   
ICM – Insertable Cardiac Monitor  
IRB – Institutional Review Board  
IRL – Implantable Loop Recorders   
ITT – Intention -to-treat 
Non-healing Pocket Deh iscence – Separation of wound edges around the insertion 
site of the device that has not healed ; excludes  hematoma, seroma, infection, and 
erosion.  
NYHA – New York Heart Association  
  
Version 11 -Apr-2016  Page  46 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
OAC – Oral Anticoagulant  
Pocket Pain  – Pain greater than 1 week post -insertion requiring intervention with a 
narcotic  (if narcotics are not already prescribed)  or requiring pocket revision.  
Primary Infection  – Infection requiring  intervention such as  IV antibiotics, device 
removal, or hospitalization. Excludes superficial infec tion that is resolved with outpatient 
antibiotics . 
sECG – Subcutaneous Electrocardiogram  
Skin Erosion  – Deterioration of tissue over the implant site  or the movement of the 
device or antenna through the skin.  
Secondary Infection  – Infection that is determi ned not to be a result of the insertion 
procedure, but may be due to previous course of therapy  or pre -existing infection . 
Superficial Infection  – Infection that only involves the skin and surrounding 
subcutaneous tissue around the incision site of the ins ertion procedure that is treated on 
an outpatient basis or a stitch abscess that requires outpatient antibiotics.  
Surrounding tissue damage  – Significant physical d amage to the pocket or 
surrounding subcutaneous tissue s as a result of insertion procedure.   
Suspected Device Failure – Device issue that is believed to be an electrical 
malfunction.  
  
Version 11 -Apr-2016  Page  47 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
APPENDIX B : DETAILED PROCEDURES  
I. Insertion Visit  Device Data  
R-Wave Amplitudes   
 Interrogate the BioMonitor 2  
 Freeze window  to capture the R -waves as shown in Figure 11 using the “
 ” 
icon.   
Figure 11: Freeze Window  
 
 Provide the peak amplitudes of two R -waves using the calipers. Document 
the two  R-wave amplitudes on a study worksheet or medical record . “Print” 
and “Store” this F reeze  window (at least  25 mm/s).  
 While in the F reeze  window with the R -waves selected, print a screenshot by 
following  Figure 12. To do this , connect the USB flash drive (orange arrow) to 
the Programmer  USB port. Open left paper tray (green arrow). Press the Stop 
and the 10 button (blue arrow).  
Figure 12: Print Screen Instructions  
 
  
Version 11 -Apr-2016  Page  48 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
 
II. Wound Check Visit and 90 -day Follow -up visit  Device Data  
Please follow these steps when BIOTRONIK Home Monitoring® is not available .   
Average R-Wave Amplitude  
 Under  “Diagnostics”  “Sensing”  “R-wave trend,” put the caliper on the  
date of visit , and record the value displayed above the graph with the date of 
visit selected .  
Figure 13: R-Wave Amplitude Trend  
 
 While in the R-Wave trend  window with the  date of visit selected , print a 
screenshot by following  Figure 12. To do this, connect the USB flash drive 
(orange arrow)  to the Programmer  USB port. Open left paper tray (green 
arrow). Press the Stop and the 10 button (blue arrow).  
Average Noise Burden  
 Under  “Diagnostics”  “Sensing”  “Noise duration  trend,” put the caliper on 
the date of visit , and record the value displa yed above the graph with the date 
of visit selected .  
  
Version 11 -Apr-2016  Page  49 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Figure 14: Noise Duration Trend  
 
 
 While in the Noise duration trend  with the  date of visit selected , print a 
screenshot by following  Figure 12. To do this, c onnect the USB flash drive 
(orange arrow) to the Programmer  USB port. Open left paper tray (green 
arrow). Press the Stop and the 10 button (blue arrow).  
III. 90-day visit Device Data “Read out”  
Please follow t hese steps at the end of the 90-day visit .   
 Connect a USB flash drive to the Programmer  
 Apply the programming wand above the BioMonitor 2.  
 Download the data from the BioMonitor 2 memory while the subject is in a 
reclined position. Select “More”  “BioMonitor 2”  “Device Data”  “Rea d 
out”. The data transmission can take about 5 minutes.  
  
Version 11 -Apr-2016  Page  50 of 50 
CONFIDENTIAL: Do not copy or distribute without BIOTRONIK approval  
Figure 15: Device Data Read Out  
 
 Open the “Data Manger” and select the correct subject and corresponding 
visit date.  
 Under  “Options ,” select “Backup” and “PDF” under the US B column as  shown 
in Figure 16. Verify that “Backup” is selected ; this is the only way to export the 
raw data with the follow -up information . Note that the automatic export option 
is not required.  
Figure 16: Export Options for data storage on USB stick  
 
 After closing the “Options” window, open “Preview” and select all follow -up 
data.  
 Close the “Preview” window and select “Export.”  